Catalysts About BillionToOne BillionToOne is a molecular diagnostics company focused on prenatal screening and oncology testing using its single molecule next generation sequencing platform. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About BillionToOne BillionToOne is a molecular diagnostics company focused on prenatal testing and oncology using its single molecule next-generation sequencing platform. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About BillionToOne BillionToOne develops highly sensitive molecular diagnostic tests in prenatal health and oncology using its single molecule next-generation sequencing platform. What are the underlying business or industry changes driving this perspective?Read more
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.
